Finally, Exo from AML MSCs and not from healthy MSCs protected a leukemic cell line carrying FLT3 internal tandem duplication from treatment with a specific FLT3 inhibitor [113]. This evidence concerns the gene FLT3 and acute myeloid leukemia.